SUPN צמיחת רווח למניה השנה supernus.com

Supernus Pharmaceuticals (SUPN) faces the threat of patent expirations and pressure from generics. High barriers to entry are maintained by strict regulatory oversight and costly research. Demand for neurological drugs remains stable, independent of economic cycles. Annual EPS progress visualizes the earnings per share trend, while 23.50 determines the current value of the metric.
פילוחים אנליטיים ודוחות נתונים של חברת Supernus Pharmaceuticals (SUPN)

This metric measures the annual growth of net income per share, filtering out market noise and demonstrating the business's actual resilience to external shocks. Analyzing the history of annual net income per share growth allows for an assessment of the effectiveness of Supernus Pharmaceuticals (SUPN) portfolio diversification between the epilepsy and ADHD therapy segments, confirming the company's ability to mitigate the risks of narrow specialization in CNS drugs.